NCORP of the Carolinas is positioned to provide a sustained, powerful influence on cancer care through research in the community setting. The investigators commit to shift current research and clinical practice paradigms based on the outcomes of NCTN research. The goals of NCORP of the Carolinas are as follows: to engage community oncologists and other medical specialists in NCTN cancer control, prevention, and care delivery research, as well as quality-of-life studies embedded within treatment and imaging studies; to offer the adult and pediatric communities cancer control, prevention, treatment and care delivery trial opportunities; to engage, recruit and enroll participants from the community inclusive of minorities, underrepresented, and underserved populations; to ensure all eligible participants are offered the opportunity for biospecimen collections; to inform the community of advances made through research; to assure accurate and timely data submission and protocol compliance; to participate with the respective research bases in concept development and identification of study opportunities for disparities in the community; to enhance and improve involvement of patient advocates by including advocates in research concepts and recruitment strategies; and to mentor new investigators, partners, and research staff. The expansion of GHS (Upstate) and Palmetto Health System (Midlands) into the SC Health Company and the joint facilities and resources more than adequately support future growth and accruals through NCORP of the Carolinas cancer initiatives. More than 300 clinical trials are active at any given time at the GHS Cancer Institute and include Phase I, Phase II, Phase III treatment trials, prevention trials, symptom management trials, and quality of life trials, all of which provide patients with the latest technology throughout their cancer care continuum. Research offerings across the spectrum from prevention to palliative care ensure patients receive the best care possible. New research initiatives include state-of-the-art genetic mapping for molecular targets that enable patients to stay in the catchment area for cutting-edge treatment tailored specifically to them. Data management is important to both the clinical and business management of cancer services. NCORP of the Carolinas is poised to succeed in all aspects of the NCORP mission and contribute meaningfully to the NCORP goals by engaging patients and conducting the anticipated range of clinical trials and human subject studies.

Public Health Relevance

A robust clinical trials program is relevant to achieving advances in addressing unmet needs of cancer patients in the realm of treatment, cancer control, prevention, and care delivery. NCORP of the Carolinas is positioned to provide a sustained, powerful influence on cancer care through research in the community setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189972-06
Application #
9771793
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-23
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Prisma Health-Upstate
Department
Type
DUNS #
077990745
City
Greenville
State
SC
Country
United States
Zip Code
29605
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32